Friulchem SpA
MIL:FCM
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
0.705
1.05
|
| Price Target |
|
We'll email you a reminder when the closing price reaches EUR.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Friulchem SpA
Friulchem SpA
Cost of Revenue
Friulchem SpA
Cost of Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cost of Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Friulchem SpA
MIL:FCM
|
Cost of Revenue
-€21.9m
|
CAGR 3-Years
-16%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
N/A
|
|
|
Newron Pharmaceuticals SpA
SIX:NWRN
|
Cost of Revenue
-€462k
|
CAGR 3-Years
-45%
|
CAGR 5-Years
18%
|
CAGR 10-Years
N/A
|
|
|
Recordati Industria Chimica e Farmaceutica SpA
MIL:REC
|
Cost of Revenue
-€725.4m
|
CAGR 3-Years
-21%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
-8%
|
|
|
P
|
Pierrel SpA
MIL:PRL
|
Cost of Revenue
-€9.7m
|
CAGR 3-Years
-13%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
-16%
|
|
|
Shedir Pharma Srl Unipersonale
MIL:SHE
|
Cost of Revenue
-€23.6m
|
CAGR 3-Years
-10%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
N/A
|
|
Friulchem SpA
Glance View
Friulchem SpA engages in the research and development of pharmaceutical products for third party contract development and manufacturing organizations. The company is headquartered in Vivaro, Pordenone and currently employs 37 full-time employees. The company went IPO on 2019-07-25.
See Also
What is Friulchem SpA's Cost of Revenue?
Cost of Revenue
-21.9m
EUR
Based on the financial report for Dec 31, 2023, Friulchem SpA's Cost of Revenue amounts to -21.9m EUR.
What is Friulchem SpA's Cost of Revenue growth rate?
Cost of Revenue CAGR 5Y
-12%
Over the last year, the Cost of Revenue growth was 24%. The average annual Cost of Revenue growth rates for Friulchem SpA have been -16% over the past three years , -12% over the past five years .
You don't have any saved screeners yet
